Pull to refresh
Logo
Daily Brief
Following Why Ranks Sign Up
Researchers discover a hidden 'mini metabolism' operating directly on human DNA

Researchers discover a hidden 'mini metabolism' operating directly on human DNA

New Capabilities

Over 200 energy enzymes found bound to chromatin, with unique patterns across tissues and cancers

March 6th, 2026: Peer-reviewed study published in Nature Communications

Overview

For decades, biologists treated the cell's energy-producing machinery and its DNA-reading machinery as separate systems operating in separate compartments. A study published March 6 in Nature Communications upends that assumption: more than 200 metabolic enzymes, many of them normally associated with energy production in mitochondria, are physically attached to human DNA inside the nucleus. About 7% of all proteins bound to chromatin turn out to be metabolic enzymes, forming what the researchers describe as a 'mini metabolism' within the nucleus itself.

The finding matters because each tissue and cancer type displays its own distinct pattern of nuclear enzymes, a signature the team calls a 'nuclear metabolic fingerprint.' Oxidative phosphorylation enzymes, for instance, are abundant on the chromatin of breast cancer cells but largely absent from lung cancer cells. That tissue-specific variation opens a new front for cancer diagnostics and targeted therapies, and raises a fundamental question: how do enzymes far too large for the nucleus's usual import channels get inside?

Play on this story Voices Debate Predict

Key Indicators

200+
Metabolic enzymes found on DNA
Enzymes normally associated with energy production, now confirmed as physically bound to chromatin inside the nucleus.
7%
Chromatin-bound proteins that are metabolic
Roughly one in fourteen proteins attached to the DNA-protein complex are metabolic enzymes, far more than previously assumed.
44
Cancer cell lines profiled
The study analyzed 44 cancer cell lines and 10 healthy cell types across 10 different tissues.
10
Tissue types studied
Healthy cell types from 10 distinct tissues were profiled, each showing unique nuclear enzyme patterns.

Interactive

Exploring all sides of a story is often best achieved with Play.

Charles Darwin

Charles Darwin

(1809-1882) · Victorian Era · science

Fictional AI pastiche — not real quote.

"How remarkable that Nature, ever economical in her designs, should employ the same metabolic machinery for two great purposes — yet how much more remarkable that we required nearly two centuries after my own humble observations to discover she had hidden one workshop inside another. The cell, it would seem, is as reluctant to surrender its deepest secrets as my colleagues were to accept natural selection — though I confess the nucleus concealing entire enzymatic assemblies of such considerable dimensions strikes me as rather more audacious than anything I witnessed among the finches of the Galápagos."

Ever wondered what historical figures would say about today's headlines?

Sign up to generate historical perspectives on this story.

Log in Sign Up

People Involved

Sara Sdelci
Sara Sdelci
Leading ongoing research into chromatin metabolism and cancer
 Savvas Kourtis
Savvas Kourtis
Researcher at the Centre for Genomic Regulation

Organizations Involved

Centre for Genomic Regulation (CRG)
Centre for Genomic Regulation (CRG)
Research Institute
Home institution for the nuclear metabolic fingerprint discovery

An international biomedical research center in Barcelona focused on understanding the complexity of life from the genome to the cell to whole organisms.

Timeline

  1. Peer-reviewed study published in Nature Communications

    Publication

    The team published native chromatome profiling results in Nature Communications, revealing over 200 metabolic enzymes on DNA across 44 cancer cell lines and 10 healthy cell types, establishing the concept of a nuclear metabolic fingerprint.

  2. Chromatome profiling preprint posted on bioRxiv

    Publication

    Kourtis, Sdelci, and colleagues posted a preprint describing comprehensive chromatome profiling across cancer lineages and healthy samples, identifying widespread metabolic enzyme presence on chromatin.

  3. Sdelci lab established with ERC grant to study chromatin metabolism

    Research

    Sara Sdelci joined the Centre for Genomic Regulation in Barcelona and received a European Research Council Starting Grant to investigate the role of metabolic enzymes on chromatin in cancer.

  4. Review establishes 'moonlighting' enzyme concept

    Publication

    A review in Trends in Biochemical Sciences documented how metabolic enzymes can perform non-metabolic functions in the nucleus, coining the term 'moonlighting' for this dual role.

  5. First reports of glycolytic enzymes in the nucleus

    Discovery

    Researchers first observed glycolytic enzymes inside the cell nucleus, though these findings were not widely pursued for decades.

  6. Otto Warburg observes altered metabolism in tumors

    Discovery

    German physiologist Otto Warburg discovered that tumor cells consume far more glucose than surrounding tissue and ferment it to lactate even in the presence of oxygen, a phenomenon later named the Warburg effect.

Scenarios

Predict which scenario wins. Contrarian picks score more — points lock in when the scenario resolves.

Log in to predict. Track your picks, climb the leaderboard. Log in Sign Up
1

Nuclear metabolic fingerprints become a new class of cancer biomarker

If the tissue-specific enzyme patterns hold up in larger clinical cohorts, nuclear metabolic fingerprints could join existing biomarker panels for cancer classification and early detection. The distinct difference between breast and lung cancer enzyme profiles suggests high discriminatory power. Clinical validation studies would be needed, but the finding that each cancer type has a unique signature is the kind of result that diagnostic companies watch closely.

Discussed by: The study authors and cancer diagnostics researchers writing in Frontiers in Oncology and Biomarker Research
Consensus —
2

Targeting nuclear metabolic enzymes yields new cancer drugs

The discovery that nuclear enzymes help repair DNA damage in cancer cells points to a specific therapeutic vulnerability. Many chemotherapies work by damaging cancer cell DNA. If nuclear metabolic enzymes help cancer cells survive that damage, blocking those enzymes could make existing treatments more effective. Drug development would require identifying which nuclear enzymes are essential for cancer cell survival and designing molecules that reach them inside the nucleus.

Discussed by: Researchers at the CRG and reviewers in npj Metabolic Health and Disease and Nature Reviews Drug Discovery
Consensus —
3

Discovery of the transport mechanism reshapes nuclear biology

Many of the enzymes found on chromatin are far larger than the size limit normally enforced by nuclear pore complexes. Identifying how these bulky proteins bypass the usual size restrictions could reveal an entirely new transport mechanism. Such a discovery would have implications well beyond cancer, potentially rewriting textbook models of how cells regulate what enters the nucleus.

Discussed by: Nuclear pore complex researchers and the study authors, who flagged this as an open question
Consensus —
4

Findings remain a research curiosity without clinical translation

The history of cancer metabolism is littered with promising findings that took decades to translate into treatments. The Warburg effect was described in the 1920s but only began informing drug development in the 2000s. Nuclear metabolic fingerprints may similarly prove real but difficult to exploit clinically, particularly if the enzyme patterns are too variable across individual patients or too technically demanding to measure at scale.

Discussed by: Skeptics within the metabolism-epigenetics field, noting the long gap between the Warburg effect's discovery and therapeutic impact
Consensus —

Historical Context

The Warburg Effect (1920s)

1923-1930s

What Happened

Otto Warburg, a German physiologist, discovered that cancer cells consume enormous amounts of glucose and ferment it to lactate even when oxygen is available, unlike normal cells. He published his first paper on this observation in 1923 and won the Nobel Prize in Physiology or Medicine in 1931 for related work on respiratory enzymes.

Outcome

Short Term

The scientific community acknowledged the observation but largely set it aside, as the molecular tools to investigate it did not yet exist.

Long Term

It took roughly 80 years for the Warburg effect to drive drug development. Today, the PET scan, which detects tumors by their elevated glucose uptake, is one of oncology's most important diagnostic tools, and cancer metabolism is a major therapeutic target.

Why It's Relevant Today

The nuclear metabolic fingerprint discovery follows the same arc: a fundamental observation about how cancer cells handle energy differently. The Warburg effect shows both the potential payoff and the long timeline between metabolic discovery and clinical impact.

The ENCODE Project reveals 'junk DNA' is functional (2012)

September 2012

What Happened

The Encyclopedia of DNA Elements project, a consortium of 442 scientists, published 30 papers simultaneously showing that at least 80% of the human genome previously dismissed as 'junk DNA' actually serves biochemical functions, including gene regulation. The finding overturned a decades-old assumption that most DNA was useless.

Outcome

Short Term

The results sparked intense debate about the definition of 'functional' and reshaped how researchers studied non-coding regions of the genome.

Long Term

ENCODE's regulatory maps became essential infrastructure for understanding disease-linked genetic variants and enabled new approaches to gene therapy and precision medicine.

Why It's Relevant Today

Like ENCODE revealed hidden function in DNA once called junk, the chromatome study reveals hidden function in enzymes once thought to operate only outside the nucleus. Both discoveries expanded the map of what cells actually do with their molecular machinery.

Discovery of epigenetic modifications and cancer (1980s-2000s)

1983-2004

What Happened

Starting with the discovery of abnormal DNA methylation in cancer cells in 1983, researchers gradually established that chemical modifications on DNA and its packaging proteins could activate or silence genes without changing the DNA sequence itself. By 2004, the first epigenetic drug, azacitidine, received approval from the Food and Drug Administration for treating myelodysplastic syndromes.

Outcome

Short Term

The epigenetics field grew rapidly, with dozens of labs identifying new modifications and their roles in cancer progression.

Long Term

Epigenetic drugs are now a multi-billion-dollar therapeutic class, and epigenetic biomarkers are used in cancer screening tests like the Epi proColon blood test for colorectal cancer.

Why It's Relevant Today

Nuclear metabolic enzymes may represent a new layer of regulation sitting at the intersection of metabolism and epigenetics. If these enzymes modify chromatin function, they could expand the druggable targets in epigenetic cancer therapy.

Sources

(8)
+2
Nature Communications SciTechDaily Medical Xpress Bioengineer.org Mirage News EurekAlert! bioRxiv Centre for Genomic Regulation